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Abstract
Background: We found that selenium-binding protein 1 (SBP1) was progressively decreased in the human
bronchial epithelial carcinogenic processes. Knockdown of SBP1 in immortalized human bronchial epithelial cell line
16HBE cells significantly increased the efficiency of B[a]P-induced cell transformation. However, the relationship
between SBP1 expression and clinicopathological factors of patients has not been defined completely. The specific
role of SBP1 in prognosis of lung squamous cell carcinoma (LSCC) is still unknown.
Methods: Tissue samples from 82 patients treated by pulmonary lobectomy for LSCC were used.
Immunohistochemistry and western blotting were used to detect the expressions of SBP1 protein. The relationships
between the expression level of SBP1 and the clinicopathological features of patients were analyzed. Cox
proportional hazard regression analysis and Kaplan–Meier method were used to perform survival analysis.
Results: Expressions of SBP1 proteins were significantly lower in LSCC tissues than that in the corresponding
normal bronchial epithelium (NBE) tissues (P = 0.000). In LSCC, The expression levels of SBP1 had not correlated
with patients’ age, gender, smoking state, primary tumor stages (T), TNM clinical stages, and distant metastasis (M)
(P > 0.05). However, downregulation of SBP1 was significantly associated with higher lymph node metastasis and
lower overall survival rate (P < 0.05). Cox regression analysis indicated low expressions of SBP1 can be an
independent prognostic factor for poor overall survival in LSCC patients (P = 0.002).
Conclusions: Downregulation of SBP1 may play a key role in the tumorigenic process of LSCC. SBP1 may be a
novel potential prognostic factor of LSCC.
Keywords: Selenium-binding protein 1, Lung squamous cell carcinoma, Prognosis
Background
In the global scale, lung cancer is one of all common car-
cinoma, which always keeps the leading position, and is
the first cancer in the morbidity and mortality of carcin-
oma. According to the GLOBOCAN 2008 data, there are
23 % of total cancer-related mortalities and 17 % of newly
diagnosed cancer cases for primary lung cancer [1]. Over
the past 30 years in China, the mortality rate of lung can-
cer has increased by 465 % [2], it is responsible for more
deaths than prostate, colon, and breast tumors combined
[3]. Although there are great advances recently in the can-
cer treatments, the prognosis of patients with lung cancer
is poor even after curative surgery and chemotherapy, the
rate of 5-year survival is less than 15 % [4]. The main rea-
sons for the low survival rate of the patients could involve
the lack of sensitive and specific biomarkers for prognosis
of lung cancer. Therefore, it is necessary to identify the
biomarkers for the prognosis of lung cancer that lead to
enhancing more effective individual therapies, reduce the
mortality, and increase 5-year survival rate.
Classically, lung cancer is pathologically classified into
non-small cell lung cancer (NSCLC) and small cell lung
cancer (SCLC) [5]. NSCLC is divided into the several
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histologic subtypes: squamous cell carcinoma (SCC),
adenocarcinoma (ADC), and large cell carcinoma (LCC).
SCC is still the most common histologic type of primary
lung cancers in developing countries, although its ratio
has decreased while that of adenocarcinoma increased
over the years [6].
Selenium is an essential trace element for a lot of bio-
logic processes and possesses anti-carcinogenic proper-
ties. Forty years ago, supplemental dietary selenium was
found to play an important role in decreasing cancer risk
[7]. Selenium deficiency in diet can increase incidence of
cancers, including liver, prostate, lung, and colorectal
cancers [8]. Its antitumor functions are mediated with
selenium-binding protein 1 (SBP1, SELENBP1, hSP56)
via binding selenium covalently [9, 10]. SBP1 can express
abundantly in many normal human tissues [11, 12]. The
expressions of SBP1 were reported to decrease markedly
in numerous tumor types compared with their corre-
sponding normal tissues. The expression reduction is as-
sociated with poor outcome in lung adenocarcinomas,
breast cancer, gastric cancer, colorectal cancer, and renal
cell carcinoma [13–17]. In our previous study, we had
found that SBP1 was progressively decreased in the hu-
man bronchial epithelial carcinogenic processes and
SBP1 expression could distinguish normal bronchial epi-
thelium (NBE) from preneoplastic lesions and invasive
LSCC. Knockdown of SBP1 in immortalized human
bronchial epithelial cell line 16HBE cells significantly in-
creased the efficiency of B[a]P-induced cell transform-
ation [18]. However, there have been very few reports
about the relationship between SBP1 expression and
clinicopathological factors in LSCC. The specific role of
SBP1 in prognosis of LSCC is still unknown. Therefore,
in this study, we investigated the expression of SBP1 in
LSCC and corresponding NBE tissues by immunohis-
tochemistry and western blotting, evaluated the rela-
tionship of SBP1 expression and clincopathological
factors, and further determined its prognostic signifi-




Anti-SBP1, β-actin monoclonal antibody, and violet-free
methyl green were from Sigma–Aldrich. Horseradish
peroxidase (HRP)-labeled secondary antibodies (goat
anti-mouse IgG) and ECL detection reagent were pur-
chased from Amersham Biosciences. Polyvinylidene
difluoride (PVDF) membranes were from Millipore. Pro-
tease inhibitor was purchased from Roche Molecular
Biochemicals. Coomassie (Bradford) Protein Assay Kit
was obtained from Pierce. Standard solutions (bovine
serum albumin) were from Merck Germany. SP kit and
DAB developer were bought from Fuzhou Maixin.
Patients and tissue specimen gender
Eighty-two patients with histologically confirmed LSCC
were included in this study, all of whom were recruited
from December 2007 to July 2008 at the Department of
Cardiothoracic Surgery, The Second Affiliated Hospital
of the University of South China. There were no age,
gender, ethnicity, or tumor stage restrictions on patient
enrolment. As variables possibly affect prognosis, we
collected clinicopathological features including age, gen-
der, smoking state, primary tumor (T) stage, TNM stage,
regional lymph node metastasis, and distant metastasis
determined according to the sixth edition of AJCC can-
cer staging manual [19]. All patients were selected at
their first diagnosis and had not received chemotherapy,
radiotherapy, and/or immunotherapy before pulmonary
lobectomy. Every LSCC sample was matched with the
corresponding normal bronchial epithelium tissues usu-
ally 5–10 cm away from the border of the main tumor
lesions in the same patient. After surgeries, bronchi and
tumor tissues were removed from the resected pulmon-
ary lobes. Sixteen pairs of LSCC tissues and matched
bronchi were stored at −80 °C for laser capture micro-
dissection (LCM) and western blotting. Another 66 pairs
were formalin-fixed and paraffin-embedded for immu-
nohistochemistry. The diagnosis of primary LSCC and
the corresponding NBE tissues was confirmed by two in-
dependent pathologists who were blinded to the original
diagnoses. All of the survival status was regularly evalu-
ated from the date of primary curative surgeries to July
31, 2013. Only the records of patients who had died of
LSCC were considered as uncensored. Patients who died
of a cause not related to LSCC and patients who were
alive at the end of follow-up interval were recorded as
censored. Every patient signed an informed consent
form for the study which was approved by the local eth-
ical committee. All clinical investigations were con-
ducted according to the principles expressed in the
Declaration of Helsinki.
Laser capture microdissection
LCM was performed using a Leica AS LMD system
(Leica) to purify the interest cells from LSCC tissues and
matched NBE tissues as described previously [20].
Seven-micrometer-thick frozen sections of fresh LSCC
and NBE were prepared using a Leica CM 1900 cryostat
(Leica) at −25 °C. The sections were placed on
membrane-coated glass slides (Leica), fixed in 75 % alco-
hol for 30 s, and stained with 0.5 % violet-free methyl
green (Sigma). Following staining, all solutions for stain-
ing were supplemented with protease inhibitor cocktail
tablets (Roche Molecular Biochemicals), the stained sec-
tions were air-dried and then subjected to LCM. Each
cell population was determined to be 95 % homogeneous
by microscopic visualization of the captured cells (Fig. 1).
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The microdissected cells were dissolved in lysis buffer
(2 M thiourea, 7 M urea, 0.1 mM phenylmethylsulfonyl
fluoride, 65 mM dithiothreitol) at 4 °C for 1 h and then
centrifuged at 12,000 rpm for 30 min at 4 °C. The super-
natant was transferred to a fresh tube and stored at −80 °C
until western blotting.
Measurement of tissue sample protein concentrations
The concentration of total proteins of tissue samples
was decided according to Bradford assay method involv-
ing reacting the tissue samples with a dye that binds
proteins. To measure the protein concentration, stand-
ard solutions (bovine serum albumin, Merck Germany)
and tissue samples were prepared and Bradford reagent
was added. The absorbance of tissue samples and stand-
ard solutions were measured at 595 nm after 10 min in-
cubation at room temperature. A standard curve was
prepared using the standard solution absorbance and the
protein concentration of samples was estimated [21].
Western blotting
Sixteen pairs of microdissected fresh LSCC and matched
NBE tissues were used for western blotting as previously
described by us [20]. In brief, 30 μg of lysates were sepa-
rated by 10 % SDS-PAGE and transferred to PVDF
membranes. Blots were incubated with primary anti-
SBP1 antibody (1:500; Sigma) overnight at 4 °C, followed
by incubation with a horseradish peroxidase-conjugated
secondary antibody (1:3000; Amersham Biosciences) for
1 h at room temperature. The signal was visualized with
ECL detection reagent (Amersham Biosciences) and quan-
titated by densitometry using ImageQuant image analysis
system (Storm Optical Scanner, Molecular Dynamics). β-
Actin was simultaneously detected using mouse anti-β-
actin antibody (1:3000; Sigma) as a loading control.
Immunohistochemistry and evaluation of staining
Immunohistochemistry was done on formalin-fixed and
paraffin-embedded tissue specimens including 66 cases
of LSCC and 66 cases of matched NBE. Briefly, 4 μm of
tissue sections was deparaffinized, rehydrated, and
treated with an antigen retrieval solution (10 mmol/l so-
dium citrate buffer, pH 6.0). The sections were incubated
with anti-SBP1 (1:50; Sigma–Aldrich) antibody overnight
at 4 °C and then were incubated with 1:1000 dilution of
biotinylated secondary antibody. Immunoreactivity was vi-
sualized using 3′,3′-diaminobenzidine tetrachloride (DAB;
Sigma–Aldrich) and counterstained with hematoxylin. In
negative controls, primary antibodies were replaced by PBS.
Immunostaining was blindly evaluated by two investi-
gators in an effort to provide a consensus on staining
patterns under light microscopy. A quantitative score
was performed by adding the score of staining intensity
and the score of staining area for each case to assess the
expression levels of the proteins as previously described
by us [20]. At least 10 high-power fields were chosen
randomly, and >1000 cells were counted for each sec-
tion. First, a quantitative score was performed by esti-
mating the percentage of immunopositive cells: 0, no
staining of cells in any microscopic fields; 1+, <30 % of
Fig. 1 Purification of human normal bronchial epithelium and lung squamous cell carcinoma tissues by LCM. a H.E. staining of NBE (a), NBE
before (b) and after (c) LCM, and captured NBE cells (d). b H.E. staining of LSCC (a), LSCC before (b) and after (c) LCM, and captured LSCC cells (d)
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tissue stained positive; 2+, between 30 and 60 % stained
positive; and 3+,>60 % stained positive. Second, the in-
tensity of staining was scored by evaluating the average
staining intensity of the positive cells (0, no staining; 1+,
mild staining; 2+, moderate staining; 3+, intense stain-
ing). Finally, a total score (ranging 0~6) was obtained by
adding the area score and the intensity score for each
case. A combined staining score of ≤2 was considered to
be low staining (negative expression); a score between 3
and 4 was considered to be moderate staining (expres-
sion); that between 5 and 6 was considered to be strong
staining (high expression).
Statistical analysis
All statistical analyses were performed using SPSS 15.0
software. The difference of SBP1 protein expressions be-
tween NBE and LSCC and the relationships between
SBP1 expression and clinicopathological factors were an-
alyzed using the χ2 test. Follow-up by telephone was car-
ried out to obtain the information of patients’ outcomes.
The follow-up period lasted up to 60 months. Overall
survival was calculated from the time of surgery to the
time of death. The deaths of the patients caused by
LSCC were considered as outcomes; the deaths of the
patients by other causes were censored, and the missing
values were replaced by the series mean method. Overall
survival curves were obtained using the Kaplan–Meier
method, and log-rank testing was used to evaluate the
statistically significant differences. Cox regression ana-
lysis was used to evaluate the prognostic significance of
clinicopathological factors. P < 0.05 was considered as
statistical significance.
Results
Expression of SBP1 in LSCC and NBE
SBP1 protein distribution was observed primarily in the
cytoplasm and nucleus of cells (Fig. 2a). Immunohisto-
chemical analysis demonstrated that SBP1 protein expres-
sion decreased significantly in LSCC compared to its
abundance in the corresponding NBE. Among the 66 LSCC
tissue samples, 63.6 % (42/66) stained were negative (low
expression), only 36.4 % (24/66) stained were positive (dif-
fuse cytoplasmic staining, moderate and high expression).
However, there were 13.6 % (9/66) stained negative (low ex-
pression) and 86.4 % (57/66) stained positive (strong diffuse
cytoplasmic staining and nuclear staining) among the 66
NBE tissue samples (Table 1, P < 0.05). The expressional
levels of SBP1 protein were further verified by western blot-
ting analysis, which were performed with 16 pairs of micro-
dissected fresh LSCC and matched NBE tissues. Similarly,
the expression of SBP1 protein was also found to be down-
regulated in all 16 human primary LSCC tissues compared
with their matched NBE tissues (Fig. 2b, c). These results
demonstrated that the expressional levels of SBP1 protein
Fig. 2 Expression of SBP1 in the human normal bronchial epithelium and lung squamous cell carcinoma tissues. a A representative result of
immunohistochemistry shows expression of SBP1 is reduced in LSCC compared with the matched NBE. Original magnification, ×200. b A
representative result of western blotting shows the expressions of SBP1 in the microdissected NBE and LSCC; c histogram shows the expression
levels of SBP1 in NBE and LSCC tissues as determined by densitometric analysis. β-Actin is used as the internal loading control. Columns, mean
from 16 cases of tissues; bars, SD (*P < 0.05 by one-way ANOVA)
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were markedly decreased in LSCC tissues compared with
the corresponding NBE tissues.
Correlation of SBP1 expression in LSCC with
clinicopathologic factors
Table 2 showed the correlation of several clinicopatho-
logic factors with SBP1 expression status among 66
cases of primary LSCC. The expression levels of SBP1
had not correlation with patients’ age, gender, smoking
state, primary tumor stages (T), TNM clinical stages,
and distant metastasis (M) (P > 0.05). However, SBP1
expressions were correlated with regional lymph node
metastasis (N) (P < 0.05). These results might indicate
that the reduction of SBP1 be associated with the pro-
gression of LSCC.
Correlation of SBP1 expression and survival of patients
with LSCC
To verify whether the downregulation of SBP1 associ-
ated with the outcomes of patients with LSCC, we evalu-
ated SBP1 as a prognostic factor among 66 patients with
LSCC after surgical resection according to immunohis-
tochemical SBP1 expressions. In the end of the study, 53
patients died, 10 patients were still alive, and 3 patients
were lost during follow-up. The mean survival times of
the patients with moderate and high expressions of SBP1
was 42.0 ± 16.2 months, which was higher than that of pa-
tients with low expression of SBP1 (26.1 ± 15.1 months,
P < 0.01). The survival curves showed that the overall
survival rate was significantly decreased with decreas-
ing SBP1 expression (Fig. 3). To identify independent
predictors for survival, univariate and multivariate Cox re-
gression analyses were performed. Via univariate analysis,
Table 3 showed that survival reduction was correlated
with lymph node metastases, distant metastasis, advanced
TNM stages, and decreasing SBP1 expression. Age and
gender of patients, smoking state, and primary tumor
stages (T) did not influence survival. The four significant
prognostic factors determined by univariate analysis were
included in a subsequent stepwise multivariate analysis.
Table 1 The difference of SBP1 expression between LSCC and
normal bronchial epithelium
n Score P value
Low (0–2) Moderate (3–4) High (5–6)
NBE 66 9 24 33 0.000*
LSCC 66 42 18 6
*P < 0.05 by χ2 test
Table 2 Relationship between SBP1 expression and clinicopathological factors in lung squamous cell cancer
Variables n Score P value
Low (0–2) Moderate (3–4) High (5–6)
Age, years
<55 29 19 8 2 0.779
≥55 37 23 10 4
Gender
Male 34 22 9 3 0.852
Female 32 20 9 3
Smoking
Smoking 41 25 12 4 0.565
Non-smoking 25 17 6 2
TNM clinical stage
I–II 21 9 7 5 0.165
III–IV 45 33 11 1
Primary tumor (T) stage
T1–T2 37 27 7 3 0.075
T3–T4 29 15 11 3
Regional lymph node metastasis (N)
N0 29 14 10 5 0.022*
N1, N2, N3 37 28 8 1
Distant metastasis (M)
M0 52 30 16 6 0.053
M1 14 12 2 0
*P < 0.05 by χ2 test
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By multivariate analysis (Table 4), lymph node metastases,
distant metastasis, advanced TNM stages, and decreasing
SBP1 expression remained as the significantly independ-
ent prognostic factors for decreasing overall survival rate.
Discussion
Lung cancer is the most frequently occurring malig-
nancy with increasing incidence, and it is also the lead-
ing cause of mortality in cancer-related deaths in China
and worldwide [22, 23]. LSCC is the most common
histological type of lung cancer. At present, the TNM
staging system is considered as the most accurate pre-
dictor for LSCC [24]. Based on histopathology and ex-
tent of disease at presentation, the anatomic TNM
staging system has reached its limit in providing critical
information that may influence the strategies of
treatments. However, pathologically similar tumors with
comparable stages show a dramatically different re-
sponse to the same therapy. Although surgery is the best
therapeutic modality for patients with early stages of
LSCC, the patients with the same pathological and clin-
ical stages of LSCC display considerable variabilities in
survival. Even after radical surgery, a significant propor-
tion of patients may suffer from regional or distant re-
currence. Therefore, there is an urgent need for finding
new molecular markers that can distinguish between pa-
tients with unfavorable prognosis and others with better
prognosis. If individuals with poor prognoses could be
identified at the time of surgeries, their survival might
be prolonged using more effective adjuvant therapies.
Selenium is an essential trace element involving anti-
oxidative, antimutagenic, antiviral, and anticarcinogenic
properties [25]. Some convincing epidemiological data
showed there was a statistically significant inverse
relationship between selenium levels and cancer risk
[26–28]. It is suggested the anticancer action of selenium
might be mediated by SBP1 as it is decreased in prostate
cancer, colorectal cancer, and esophageal adenocarcin-
oma [29–31]. SBP1 displays tumor suppressor functions
and plays a role in toxification/detoxification processes,
cell growth regulation, cell motility, apoptosis, and intra-
Golgi protein transport [32–35]. A research about lung
adenocarcinoma showed SBP1 was significantly decreased
in T2 to T4 stage tumors (versus T1 stage tumors) and
bronchus-derived tumors (versus bronchioloalveolar
adenocarcinoma) [13]. Hepatocellular carcinoma patients
with lower SBP1 expression experienced shorter overall
survival periods and higher rates of disease recurrence.
SBP1 was reported as an independent risk factor for over-
all survival and disease recurrence [34]. In our previous
studies, we found that knockdown of SBP1 in immortal-
ized human bronchial epithelial cell line 16HBE cells sig-
nificantly promoted cell proliferation, inhibited apoptosis,
and increased the efficiency of B[a]P-induced cell trans-
formation [18]. However, there was little information
about the relationship of SBP1 expression and clinicopath-
ological factors of LSCC. Meanwhile, the prognostic
significance of SBP1 expression in LSCC is not yet to
be clarified.
Fig. 3 Kaplan–Meier survival plots for LSCC patients according to
the expression levels of SBP1. SBP1 expression and overall survival
(P = 0.000). P value was determined using a two-sided log-rank test
Table 3 Univariate Cox regression analysis of overall survivals
Variables Overall survival
HR (95 % CI) P value
Age (<55/≥55) 0.873 (0.558–1.365) 0.551
Gender (male/female) 1.078 (0.677–1.717) 0.752
Smoking (no/yes) 0.750 (0.481–1.171) 0.205
T stage (T1–T2/T3–T4) 1.339 (0.861–2.084) 0.196
TNM stage (I–II/III–IV) 6.060 (3.298–11.135) 0.000*
Tumor-node-metastasis (N/P) 11.021 (5.723–21.221) 0.000*
Distant metastasis (N/P) 5.813 (3.360–10.056) 0.000*
SBP1 expression (0–2/3–6) 0.385 (0.236–0.628) 0.000*
HR hazard ratio, 95 % CI 95 % confidence interval, N negative, P positive
*P < 0.05
Table 4 Multivariate Cox regression analysis of overall survivals
Variables Overall survival
HR (95 % CI) P value
TNM stage (I–II/III–IV) 0.421 (0.182–0.973) 0.043*
Tumor-node-metastasis (N/P) 0.203 (0.087–0.470) 0.000*
Distant metastasis (N/P) 0.380 (0.213–0.677) 0.001*
SBP1 expression (0–2/3–6) 2.228 (1.329–3.737) 0.002*
HR hazard ratio, 95 % CI 95 % confidence interval, N negative, P positive
*P < 0.05
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We examined SBP1 protein expression in LSCC tis-
sues using western blotting and immunohistochemistry
so as to investigate the role of SBP1 in LSCC because of
the proteins as the cellular function molecules. Our re-
sults demonstrated that SBP1 was downregulated in
LSCC compared with matched NBE tissues. The SBP1
proteins were detected both in the cytoplasm and
nucleus, using immunohistochemical staining. In all,
36.4 % (24/66) of LSCC showed positive staining of
SBP1. Our study showed that SBP1 expression was
markedly diminished in lymph node metastasis (versus
without lymph node metastasis) of patients by analyzing
the correlation between SBP1 expression and clinico-
pathologic factors. The expression levels of SBP1 corre-
lated with lymph node metastasis. The data revealed
that the median survival time in patients with low-level
expression of SBP1 appears shorter than that in patients
with moderate and high SBP1 expressions. The median
survival time of patients with SBP1 low-level expression
was 26.1 ± 15.1 months, but for patients with moderate
and high expression of SBP1, it was 42.0 ± 16.2 months.
This is the first study for evaluating the prognostic value
of SBP1 in LSCC patients. Survival analysis with Cox
proportional hazard regression analysis and Kaplan–
Meier method demonstrated that SBP1 expressions were
closely related to the survival of LSCC, and reduced
SBP1 expressions were an independently prognostic fac-
tor for poor overall survival in LSCC patients. Therefore,
the data demonstrate that SBP1 expressions have the po-
tential role for predicting the outcome of LSCC patients.
The assessment of SBP1 expressions may, therefore, be
used as an additional tool for identifying the patients at
risk of tumor progression, and it may be a helpful criter-
ion to optimize individual therapy management. Our
findings have possible clinical applications.
Conclusions
Our results indicate that SBP1 expression is reduced in
LSCC and associated with lymph node metastasis of pa-
tients. Reduced SBP1 is an independent prognostic fac-
tor for poor overall survival in LSCC patients. SBP1
could serve as a potential prognostic marker for improv-
ing tumor classification of LSCC.
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